Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Licensing Deal

Tempus AI Shares Skyrocket 30% in 6 Days Since $192.5 Million Bristol-Myers Squibb Deal

Tempus AI Secures $192.5 Million Licensing Deal with Bristol-Myers Squibb

+30.04% in 6 days $63.81 when we broke this story → $82.98 at 1:03 PM ET, 2 Nov 2026

Tempus AI has expanded its collaboration with Bristol-Myers Squibb through a multi-year data licensing agreement valued at $192.5 million. The deal provides BMS and its partner Pathos AI with access to de-identified multimodal real-world data and agentic analysis tools to accelerate therapeutic development in oncology and neurology.

Clinical trial consulting, clinical development consulting, clinical research development. Stock photo illustrating Tempus AI's licensing deal story.
Tempus AI, Inc. · Healthcare · Photo: u_qzc1eihxev / Pixabay
Key numbers
Deal value$192M
Share of market cap1.7%
Share of annual revenue15.1%

Key highlights

  • Aggregate cash payments to Tempus totaling $192.5 million over an approximate five-year term
  • Oncology agreement with BMS provides $137.5 million in fixed payments through 2031
  • Neurology license with Pathos involves up to $55 million for 500,000 patient records
  • Deployment of the Tempus Agent, a specialized agentic tool for interrogating licensed data
  • Integration of Tempus oncology data with the Pathos Foundry drug development platform

What Is the Licensing Deal?

Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the utilization of its de-identified multimodal real-world data and analysis tools. This deal includes a Statement of Work for oncology data services directly with BMS and a neurology-focused agreement with Pathos AI, which supports BMS’s therapeutic development activities. The collaboration provides the pharmaceutical partners with access to curated oncology and neurology datasets, alongside Tempus’s Lens software and new agentic data analysis tools. These resources are designed to facilitate deep interrogation of patient records, aiding in the identification of biomarkers and the optimization of clinical trial protocols for complex diseases.

Licensing Terms

  • BMS will pay $137.5 million in aggregate fixed payments for oncology data and Lens software access.
  • Payments under the oncology agreement will be invoiced quarterly through December 31, 2031.
  • Pathos will pay up to $55 million in cash for neurology data and the Tempus Agent tool.
  • Neurology fees include $50 million for record delivery at a rate of $100 per de-identified record.
  • An additional $5 million is allocated for the availability of record updates over the five-year term.

Strategic Fit

This agreement reinforces a long-standing relationship between Tempus and BMS, which dates back to a master services agreement established in 2018. By granting BMS access to the Lens platform and the newly introduced Tempus Agent tool, Tempus is embedding its agentic AI capabilities directly into the pharmaceutical giant’s research workflows. The inclusion of Pathos AI’s Foundry platform allows for a specialized focus on neurology, an area where multimodal data is increasingly critical for understanding complex disease progressions like Alzheimer’s. This deal follows a pattern of high-value expansions for Tempus, which recently signed similar agreements with Merck, Moderna, and Gilead Sciences.

Financial Context

Tempus AI maintains a significant contracted backlog, which exceeded $1.1 billion at the end of fiscal 2025. The company recently raised its full-year 2026 revenue guidance to a range of $1.595 billion to $1.605 billion, supported by an expected adjusted EBITDA of approximately $65 million. This licensing deal contributes to a diversified revenue stream that includes data services and genomic sequencing. The company is also in the process of closing its acquisition of Personalis, Inc., expected in late 2026. While the stock has seen a quarterly gain of 30.28%, it recently faced a month-to-date decline of 17.33% ahead of its third-quarter results.

Tempus AI, Inc. share price · last month
Line chart of Tempus AI, Inc.'s share price over the last month, from $64.34 on 19 Oct → $64.76 on 16 Nov; our story on 23 Oct at $63.81.

Up 1.5% since our story on 23 Oct: $63.81 when we broke it → $64.76 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$64.34
20 Oct$66.75
21 Oct$67.76
22 Oct$63.81
23 Oct$67.61
26 Oct$67.16
27 Oct$72.15
28 Oct$76.61
29 Oct$77.84
30 Oct$72.22
2 Nov$78.48
3 Nov$77.80
4 Nov$75.61
5 Nov$70.43
6 Nov$76.05
9 Nov$84.44
10 Nov$80.54
11 Nov$79.43
12 Nov$75.89
13 Nov$71.60
16 Nov$64.76

Industry Landscape

  • Bio-pharmaceutical companies are increasingly utilizing real-world data to optimize clinical trial designs.
  • AI-driven biomarker discovery has become a central focus for oncology research and development.
  • Multimodal datasets combining clinical and genomic records are replacing single-modality data silos.
  • Strategic partnerships between tech-enabled diagnostic firms and large pharma are scaling AI integration.
  • Growth in neurology R&D is driving demand for specific, longitudinal datasets in neurodegenerative diseases.
Earlier announcements by Tempus AI, Inc.
DateAnnouncementAmount
07 Oct 2026Expanded multi-year collaboration with Moderna and Merck to support commercialization of intismeran autogene (V940/mRNA-4157)Source: investors.tempus.com–
21 Sep 2026Extension of data license agreement and license agreement for RNA Foundation Model with Recursion PharmaceuticalsSource: investors.tempus.com$42.0 Million
14 May 2026Expanded strategic collaboration with Bristol Myers Squibb to optimize clinical trial designs in oncology and neuroscienceSource: investors.tempus.com–
15 Apr 2026Collaboration with Predicta Biosciences to expand access to whole-genome sequencing assay for hematologic malignancies and MRD monitoringSource: investors.tempus.com–
09 Apr 2026Expanded multi-year collaboration with Gilead Sciences to advance oncology R&D using the Lens platformSource: investors.tempus.com–
25 Mar 2026Strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation for ADC programsSource: investors.tempus.com–
Tempus AI, Inc. · financial snapshot
Share price$63.81
Market cap$11.5B
Revenue (annual)$1.3B
1-month price change-17.33%
SectorHealthcareHealth Information Services

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Tempus AI, Inc. announcing a $192.5 million licensing expansion with Bristol-Myers Squibb and Pathos AI.

Read the filing ↗

Track Tempus AI, Inc. live

Get the next Tempus AI, Inc. SEC filing seconds after it lands.

More in Partnerships

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.